Why Amarin Stock Plunged in February

Shares of mid-cap drugmaker Amarin (NASDAQ: AMRN) fell by 20.9% in February, according to data from S&P Global Market Intelligence.

The Irish biopharma hit the skids last month for two reasons.

First, investors apparently weren't entirely enthused with Amarin's fourth-quarter results released on Feb. 25.